Intuitive Surgical

ISRG

Market cap $166B

BOCA RATON, Fla.--(BUSINESS WIRE)---- $ISRG #FDAcleared--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its TiLink™ Navigation Instruments for use with the TiLink™ SI Joint Fusion System in sacroiliac joint procedures. The system is engineered for compatibility with Medtronic's StealthStation™ navigation platform, enabling enhanced precision during minimally invasive SI joint fusion surgeries.

Scores of healthcare stocks stand to benefit from the "greying of America" trend, but one you might have overlooked is Intuitive Surgical. The maker of the da Vinci robotic surgery system operates as a "razor and blades" ecosystem, profiting from both system installation and usage.

In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $467.22, indicating a +1.8% shift from the previous trading day.

Costco's competitive moat and growth runway suggest the popular retail stock will maintain its premium valuation. Robotic surgical system leader Intuitive Surgical continues its global spread.

ISRG slides nearly 20% YTD despite strong procedure growth and upgrades, as valuation concerns and macro pressures weigh on near-term upside.

Becton, Dickinson, and Company is a cheap dividend stock that may become even cheaper in a market crash. Given Intuitive Surgical's prospects in its core market, the stock would be a no-brainer in a downturn.

Intuitive Surgical's 13-15% 2026 procedure growth signals durable demand and global expansion, but macro and policy risks could test its premium valuation.

In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $462.28, marking a +2.06% move from the previous day.

Intuitive Surgical has a massive lead in its corner of the robotic-assisted surgery market. The company also has an excellent balance sheet.

The rising popularity of GLP-1 drugs is a big reason why investors are bullish on the anti-obesity market. GLP-1 drugs, however, need to be taken on an ongoing basis and come with risks.